MetaCap

BioStem Technologies (BSEM) vs TScan Therapeutics (TCRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioStem Technologies (BSEM) has outperformed TScan Therapeutics (TCRX) over the past year, losing 84.0% versus a loss of 84.8%. Over five years, BSEM leads with a -55.9% price change compared with -98.3% for TCRX. BioStem Technologies is the larger company by market cap ($12.2 million vs $9.9 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BSEM-83.98%TCRX-84.85%
+116%+11%-95%
Nov 21, 20251 yearNov 20, 2026
BSEM-25.28%TCRX-98.34%
+2716%+1242%-232%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BSEM versus TCRX key metrics
MetricBSEMTCRX
Share price$0.6351$0.1459
Market cap$12.18M$9.89M
1-day change-10.23%+2.24%
YTD return-83.33%-85.41%
1-year return-83.98%-84.85%
5-year return-55.90%-98.33%
P/E ratio (TTM)0.72—
Forward P/E2.19—
EPS (TTM)$0.88$-0.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$10.32M
Revenue growth (YoY)—+266.65%
Net income (latest FY)—$-129.77M
Operating margin—-1315.38%
Net margin—-1256.81%
52-week high$8.40$1.47
52-week low$0.5347$0.14
Distance from 52-week high-92.44%-90.07%
Analyst consensusnonehold
Avg. price target upside+1002.19%+585.40%
Average volume194.93K766.11K
Shares outstanding19.18M63.50M
Employees73138
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BioStem Technologies

BSEM stock →

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees

About TScan Therapeutics

TCRX stock →

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees

BSEM vs TCRX FAQ

Which is bigger, BioStem Technologies or TScan Therapeutics?

BioStem Technologies (BSEM) is larger, with a market capitalization of $12.18M compared with $9.89M for TScan Therapeutics (TCRX).

Which stock has performed better over the past year, BSEM or TCRX?

BSEM returned -83.98% over the past 12 months, compared with -84.85% for TCRX (price return, excluding dividends). Past performance does not predict future results.

Are BioStem Technologies and TScan Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons